James R
Prelude Technology Investments, Cambridge CB4 5PJ, UK.
Nat Biotechnol. 2000 Feb;18(2):153-5. doi: 10.1038/72597.
As the value of raw sequence data diminishes, genomics companies are evolving new competencies as providers of information, therapeutic products, or novel technology.
随着原始序列数据的价值降低,基因组学公司正在发展新的能力,成为信息、治疗产品或新技术的提供商。